Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Operating Leases (2019 - 2025)

Historic Operating Leases for Tg Therapeutics (TGTX) over the last 7 years, with Q3 2025 value amounting to $7.3 million.

  • Tg Therapeutics' Operating Leases fell 1319.63% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 1319.63%. This contributed to the annual value of $8.1 million for FY2024, which is 1189.47% down from last year.
  • Latest data reveals that Tg Therapeutics reported Operating Leases of $7.3 million as of Q3 2025, which was down 1319.63% from $7.6 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Operating Leases peaked at $10.6 million during Q3 2022, and registered a low of $7.3 million during Q3 2025.
  • In the last 5 years, Tg Therapeutics' Operating Leases had a median value of $9.8 million in 2023 and averaged $9.3 million.
  • Its Operating Leases has fluctuated over the past 5 years, first soared by 560.88% in 2022, then tumbled by 1319.63% in 2025.
  • Over the past 5 years, Tg Therapeutics' Operating Leases (Quarter) stood at $9.8 million in 2021, then grew by 5.05% to $10.3 million in 2022, then dropped by 10.76% to $9.2 million in 2023, then fell by 11.89% to $8.1 million in 2024, then decreased by 10.14% to $7.3 million in 2025.
  • Its Operating Leases stands at $7.3 million for Q3 2025, versus $7.6 million for Q2 2025 and $7.9 million for Q1 2025.